These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 160589)

  • 21. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate.
    Ofosu FA; Blajchman MA; Modi GJ; Smith LM; Buchanan MR; Hirsh J
    Br J Haematol; 1985 Aug; 60(4):695-704. PubMed ID: 2411283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Placental protein 5 is related to blood coagulation and fibrinolytic systems.
    Siiteri JE; Koistinen R; Salem HT; Bohn H; Seppälä M
    Life Sci; 1982 May; 30(22):1885-91. PubMed ID: 6213827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation.
    Fischer AM; Barrowcliffe TW; Thomas DP
    Thromb Haemost; 1982 Apr; 47(2):104-8. PubMed ID: 6179182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antithrombin III: a backward glance o'er travel'd roads.
    Seegers WH
    Adv Exp Med Biol; 1975; 52():195-215. PubMed ID: 47704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of heparin in the interaction of serine proteinases with antithrombin III.
    Stürzebecher J
    Acta Biol Med Ger; 1977; 36(11-12):1893-7. PubMed ID: 151469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heparin neutralization of PGI2: effects upon platelets.
    Saba HI; Saba SR; Blackburn CA; Hartmann RC; Mason RG
    Science; 1979 Aug; 205(4405):499-501. PubMed ID: 377493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin and protease inhibition. I. Heparin complexes with thrombin, plasmin, and trypsin.
    Smith GF; Sundboom JL
    Thromb Res; 1981 Apr 1-15; 22(1-2):103-14. PubMed ID: 6457413
    [No Abstract]   [Full Text] [Related]  

  • 28. Inhibition of factor IXa and factor Xa by antithrombin III/heparin during factor X activation.
    Pieters J; Willems G; Hemker HC; Lindhout T
    J Biol Chem; 1988 Oct; 263(30):15313-8. PubMed ID: 3262615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Actions and interactions of antithrombin and heparin.
    Rosenberg RD
    N Engl J Med; 1975 Jan; 292(3):146-51. PubMed ID: 127943
    [No Abstract]   [Full Text] [Related]  

  • 30. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
    Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
    Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticoagulating and non-enzymatic fibrinolytic activities of heparin-antithrombin III and antithrombin III-heparin-thrombin complexes in vitro and in vivo.
    Kudrjashov BA; Pastorova VE; Lyapina LA
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(5):731-42. PubMed ID: 6198257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin.
    Buchanan MR; Boneu B; Ofosu F; Hirsh J
    Blood; 1985 Jan; 65(1):198-201. PubMed ID: 3965047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin.
    Holmer E; Kurachi K; Söderström G
    Biochem J; 1981 Feb; 193(2):395-400. PubMed ID: 6914196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes of prekallikrein in the cases with disseminated intravascular coagulation syndrome.
    Sakuragawa N; Takahashi K; Shibata A
    Adv Exp Med Biol; 1979; 120B():185-93. PubMed ID: 160191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.
    Lane DA; Denton J; Flynn AM; Thunberg L; Lindahl U
    Biochem J; 1984 Mar; 218(3):725-32. PubMed ID: 6721831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The anticoagulant properties of mast cell product, chondroitin sulphate E.
    Scully MF; Ellis V; Seno N; Kakkar VV
    Biochem Biophys Res Commun; 1986 May; 137(1):15-22. PubMed ID: 3087353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 38. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma.
    Ofosu FA; Modi G; Cerskus AL; Hirsh J; Blajchman MA
    Thromb Res; 1982 Nov; 28(4):487-97. PubMed ID: 7164033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of the COOH-terminal region of antithrombin III. Evidence that the COOH-terminal region of the inhibitor enhances the reactivity of thrombin and factor Xa with the inhibitor.
    Nishioka J; Suzuki K
    J Biol Chem; 1992 Nov; 267(31):22224-9. PubMed ID: 1331047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.